XEN-augmented Baerveldt vs eyeWatch in refractory glaucoma: one-year outcomes

Session Details

Session Title: Microinvasive Glaucoma Surgery

Session Date/Time: Sunday 15/09/2019 | 14:00-16:00

Paper Time: 15:12

Venue: Free Paper Forum: Podium 4

First Author: : G.Bravetti ITALY

Co Author(s): :    K. Mansouri   A. Villamarin   K. Gillmann   N. Stergiopulos   A. Mermoud                 

Abstract Details

Purpose:

To compare the outcomes of XEN-augmented Baerveldt (XaB) versus eyeWatch combined to a Baerveldt (eWB) in refractory glaucoma.

Setting:

Retrospective study, at a tertiary glaucoma centre.

Methods:

Intraocular pressure (IOP), best corrected visual acuity (BCVA), number of antiglaucoma medications, and post-operative complications were analysed post-operatively at 1 week, 1 month, 3 months, 6 months, 9 months, and 1 year, and compared to the pre-operative baseline. Surgical success was defined as achieving an IOP ≤ 15 mmHg without need of subsequent glaucoma surgery.

Results:

Data were available from 41 eyes for the XaB group and 15 eyes for the eWB group. IOP decreased from 29.9±13.2 mmHg to 15.2±6.6 mmHg (49.2%; P < 0.0001) in the XaB group and from 26.2±6.8 mmHg to 11.9±2.8 mmHg (54.6%; P < 0.0001) in the eWB group. Antiglaucoma-medications dropped from 3.0±1.3 to 1.3±0.9 and from 3.0±0.7 to 0.8±0.9, respectively. Complete success was obtained in 14.6% of eyes in the XaB group and in 46.7% of eyes for eWB group using the ≤ 15 mmHg threshold. Overall, 41.5% and 20% of patients required reoperation, respectively.

Conclusions:

Both techniques are deemed to be safe methods to effectively reduce IOP and antiglaucoma therapy in refractory glaucoma, especially in eyes with multiple previous filtering surgeries. eyeWatch surgery seems to have a higher success rate compared to the XEN-augmented Baerveldt. Nevertheless, a high proportion of patients required reoperation.

Financial Disclosure:

gains financially from product or procedure presented